Santhe Amber van der Meulen

Ms. Santhe Amber van der Meulen

Sanquin, Amsterdam, Noord-Holland, The Netherlands
orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
PCPriyanka Chauhan
Priyanka Chauhan
Santhe Amber van der MeulenSanthe Amber van der Meulen
Santhe Amber van der Meulen
JCJoão Miguel Simões Caetano
João Miguel Simões Caetano
HGHojjat Ghasemi Goojani
Hojjat Ghasemi Goojani
DBDennis Botman
Dennis Botman
DBDirk Bald
Dirk Bald
For the design of next-generation tuberculosis chemotherapy, insight into bacterial defence against drugs is required. Currently, targeting respiration has attracted strong attention for combatting drug-resistant mycobacteria. Q203 (telacebec), an inhibitor of the cytochrome bcc complex in the mycobacterial respiratory chain, is currently evaluated in phase-2 clinical trials. Q203 has bacteriostatic activity against M. tuberculosis, which can be converted to bactericidal activity by concurrently inhibiting an alternative branch of the mycobacterial respiratory chain, cytochrome bd. In contrast, non-tuberculous mycobacteria, such as Mycobacterium smegmatis, show only very little sensitivity to Q203. In this report, we investigated factors that M. smegmatis employs to adapt to Q203 in the presence or absence of a functional cytochrome bd, especially regarding its terminal oxidases. In the presence of a functional cytochrome bd, M. smegmatis responds to Q203 by increasing the expression of cytochrome bcc as well as of cytochrome bd, whereas a M. smegmatisbd-KO strain adapted to Q203 by increasing the expression of cytochrome bcc. Interestingly, single-cell studies revealed cell-to-cell variability in drug adaptation. We also investigated the role of a putative second cytochrome bd isoform postulated for M. smegmatis. Although this putative isoform showed differential expression in response to Q203 in the M. smegmatisbd-KO strain, it did not display functional features similar to the characterised cytochrome bd variant.

29 November 2023 in Blood Advances
Verified
Journal Article
Open access
PDF file
RKRosa Krimpenfort
Rosa Krimpenfort
Santhe Amber van der MeulenSanthe Amber van der Meulen
Santhe Amber van der Meulen
HVHan Verhagen
Han Verhagen
MDMichel Driessen
Michel Driessen
GFGalina Filonova
Galina Filonova
MNmicha nethe
micha nethe
E-cadherin is a crucial regulator of epithelial cell-to-cell adhesion and an established tumor suppressor. Aside epithelia, E-cadherin expression marks the erythroid cell lineage during human but not mouse hematopoiesis. However, the role of E-cadherin in human erythropoiesis remains unknown. Because rat erythropoiesis was postulated to reflect human erythropoiesis more closely than mouse erythropoiesis, we investigated E-cadherin expression in rat erythroid progenitors. E-cadherin expression is conserved within the erythroid lineage between rat and human. In response to anemia, erythroblasts in rat bone marrow (BM) upregulate E-cadherin as well as its binding partner β-catenin. CRISPR/Cas9–mediated knock out of E-cadherin revealed that E-cadherin expression is required to stabilize β-catenin in human and rat erythroblasts. Suppression of β-catenin degradation by glycogen synthase kinase 3β (GSK3β) inhibitor CHIR99021 also enhances β-catenin stability in human erythroblasts but hampers erythroblast differentiation and survival. In contrast, direct activation of β-catenin signaling, using an inducible, stable β-catenin variant, does not perturb maturation or survival of human erythroblasts but rather enhances their differentiation. Although human erythroblasts do not respond to Wnt ligands and direct GSK3β inhibition even reduces their survival, we postulate that β-catenin stability and signaling is mostly controlled by E-cadherin in human and rat erythroblasts. In response to anemia, E-cadherin–driven upregulation and subsequent activation of β-catenin signaling may stimulate erythroblast differentiation to support stress erythropoiesis in the BM. Overall, we uncover E-cadherin/β-catenin expression to mark stress erythropoiesis in rat BM. This may provide further understanding of the underlying molecular regulation of stress erythropoiesis in the BM, which is currently poorly understood.

17 February 2026 in Blood Advances
Verified
Journal Article
Open access
Santhe Amber van der MeulenSanthe Amber van der Meulen
Santhe Amber van der Meulen
KRKarolin Roemhild
Karolin Roemhild
MDMichel Driessen
Michel Driessen
EAEmile van Den Akker
Emile van Den Akker
MNmicha nethe
micha nethe
In response to anemia, the erythroid lineage significantly expands. This growth is driven by extramedullary erythropoiesis in mice, but is additionally regulated within the bone marrow (BM) of rats, a process likely conserved in humans due to similar BM architecture. This process is, however, mostly elusive. We identified E-cadherin to mark the expansion of the erythroid lineage in BM from anemic rats. To explore the regulation of erythropoiesis in the BM in response to anemia, we studied the role of E-cadherin in the erythroid lineage of rats. As genetic methods to model erythropoiesis in rats are limited, we established a rat BM transplant model that, combined with CRISPR/Cas9 genome editing, enabled us to examine the control of E-cadherin in BM in response to anemia. We identified CD90+CD44+CD45R− cells to contain hematopoietic stem and progenitor cells (HSPCs) in rats. CD90+CD44+CD45R−-enriched HSPCs can be efficiently edited using CRISPR/Cas9, which, upon transplant, induce high BM chimerism. Importantly, we identified that recovery from irradiation-induced anemia involves 2 phases. Phase 1 is marked by expansion of erythroid precursors in the BM, supported by extramedullary erythropoiesis in the spleen. This phase is followed by a second phase, characterized by accelerated terminal differentiation, which is selectively controlled in the BM. Finally, we discovered that genetic inactivation of hematopoietic-expressed E-cadherin delays recovery from radiation-induced anemia. Our work provides novel means to expand our knowledge on hematology, and the opportunity to dissect the molecular regulation underlying the erythroid response(s) to anemia in BM, using rat models.

19 December 2020 in bioRxiv
Verified
Preprint
Open access
PDF file
HVHan J.M.P. Verhagen
Han J.M.P. Verhagen
CKCarlijn Kuijk
Carlijn Kuijk
AKAnne M. Kokke
Anne M. Kokke
LRLaurens Rutgers
Laurens Rutgers
Santhe Amber van der MeulenSanthe Amber van der Meulen
Santhe Amber van der Meulen
EAEmile van Den Akker
Emile van Den Akker
Ribonucleoproteins (RNPs) are frequently applied for therapeutic gene editing as well as fundamental research, because the method is fast, viral free, and does not rely on clonal selection. We evaluated various parameters to genetically engineer human hematopoietic stem progenitor cells (HSPCs) using sp Cas9-RNPs and achieve gene editing efficiencies up to 80%. We find that single guide RNA (sgRNA) design is critical to achieve high gene editing efficiencies. However, finding effective sgRNAs for HSPCs can be challenging, while the contribution of numerous in silico models is unclear. Here we established a time- and cost-efficient in vitro transcribed sgRNA screening model in K562 cells to identify sgRNAs that are effective in HSPCs using RNP delivery. We show that this simple screening method outperforms all in silico prediction models. Our data demonstrates that most in silico sgRNA prediction models are ineffective and we make recommendations to potentially improve their accuracy. We report that gene editing is equally efficient in distinct CD34 + HSPC subpopulations. Furthermore, no effects on cell proliferation, differentiation or in vitro hematopoietic lineage commitment were observed. Finally, no upregulation of p21 expression was found, suggesting unperturbed HSPC homeostasis. Key points: In vitro transcribed single sgRNAs (IVTsgRNA) screening in K562 outperforms in silico modeling Hematopoietic stem and progenitor cells are equally targeted by Ribonucleoproteins (RNPs) Hematopoietic stem and progenitor cells show no induction of p21 expression or effects on differentiation, proliferation and lineage commitment Graphical